期刊文献+
共找到18,627篇文章
< 1 2 250 >
每页显示 20 50 100
Blood-Letting Therapy for Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
1
作者 XIONG Xing-jiang WANG Peng-qian LI Sheng-jie 《中国结合医学杂志:英文版》 SCIE CAS CSCD 2019年第2期139-146,共8页
Objective:To evaluate the efficacy and safety of blood-letting therapy(BLT)in treatment of hypertension.Methods:A comprehensive electronic and manual bibliographic searches were performed in Cochrane Central Register ... Objective:To evaluate the efficacy and safety of blood-letting therapy(BLT)in treatment of hypertension.Methods:A comprehensive electronic and manual bibliographic searches were performed in Cochrane Central Register of Controlled Trials,Excerpt Medica Database(EMBASE),PubMed,China National Knowledge Infrastructure,Chinese Scientific Journal Database,Chinese Biomedical Literature Database,and Wanfang Database to identify randomized controlled trials(RCTs)in which hypertensive patients were treated with BLT or BLT plus antihypertensive drugs(BPAD)against placebo,no treatment or antihypertensive drugs.The Cochrane Risk Assessment Tool was used to assess the methodological quality of trials.The Review Manager 5.3 software was used for meta-analysis.Results:A total of 7 RCTs with 637 hypertensive patients from 1989 to 2017 were identified.Compared with antihypertensive drugs,blood pressure was significantly reduced by BLT(RR=1.21,95%CI:1.01 to 1.44,P=0.03;heterogeneity:P=0.06,I^2=60%)and BPAD(RR=1.25,95%CI,1.02 to 1.53,P=0.03;heterogeneity:P=0.01,I^2=71%).Moreover,a significant improvement in Chinese medicine syndrome by BLT(RR=1.32;95%CI:1.14 to 1.53,P=0.0002;heterogeneity:P=0.53,I^2=0%)and BPAD(RR=1.47;95%CI:1.06 to 2.04,P=0.02;heterogeneity:P=0.13,I^2=56%)was identified.The reported adverse effects were well tolerated.Conclusions:Although some positive findings were identified,no definite conclusions regarding the efficacy and safety of BLT as complementary and alternative approach for treatment of hypertension could be drew due to the generally poor methodological design,significant heterogeneity,and insufficient clinical data.Further rigorously designed trials are warranted to confirm the results. 展开更多
关键词 blood-letting THERAPY PHLEBOTOMY BLOOD pressure Chinese MEDICINE COMPLEMENTARY and alternative MEDICINE systematic review META-ANALYSIS randomized controlled trials
Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications 预览
2
作者 Ravi Kant Kashif M Munir +1 位作者 Arshpreet Kaur Vipin Verma 《世界糖尿病杂志:英文版(电子版)》 2019年第6期324-332,共9页
Lack of conclusive beneficial effects of strict glycemic control on macrovascular complications has been very frustrating for clinicians involved in care of patients with diabetes mellitus (DM). Highly publicized cont... Lack of conclusive beneficial effects of strict glycemic control on macrovascular complications has been very frustrating for clinicians involved in care of patients with diabetes mellitus (DM). Highly publicized controversy surrounding cardiovascular (CV) safety of rosiglitazone resulted in major changes in United States Food and Drug Administration policy in 2008 regarding approval process of new antidiabetic medications, which has resulted in revolutionary data from several large CV outcome trials over the last few years. All drugs in glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitor classes have shown to be CV safe with heterogeneous results on CV efficacy. Given twofold higher CV disease mortality in patients with DM than without DM, GLP-1 RAs and SGLT-2-inhibitors are important additions to clinician’s armamentarium and should be second line-therapy particularly in patients with T2DM and established atherosclerotic CV disease or high risks for CV disease. Abundance of data and heterogeneity in CV outcome trials results can make it difficult for clinicians, particularly primary care physicians, to stay updated with all the recent evidence. The scope of this comprehensive review will focus on all major CV outcome studies evaluating CV safety and efficacy of GLP-1 RAs and SGLT-2 inhibitors. 展开更多
关键词 Newer antidiabetic MEDICATIONS Glucagon-like peptide-1 receptor agonist Sodium-glucose cotransporter-2 inhibitors Type 2 DIABETES MELLITUS Macrovascular complications CARDIOVASCULAR outcome trials Major CARDIOVASCULAR events HEART failure PREVENTION of HEART disease
在线阅读 免费下载
Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma 预览
3
作者 Yu Akazawa Toshihiro Suzuki +3 位作者 Toshiaki Yoshikawa Shoichi Mizuno Yasunari Nakamoto Tetsuya Nakatsura 《世界荟萃分析杂志》 2019年第3期80-95,共16页
Hepatocellular carcinoma (HCC) is a highly aggressive malignant disease, with a poor clinical prognosis. Many standard therapies are often considered for HCC treatment today;however, these conventional therapies often... Hepatocellular carcinoma (HCC) is a highly aggressive malignant disease, with a poor clinical prognosis. Many standard therapies are often considered for HCC treatment today;however, these conventional therapies often fail to achieve sufficiently effective clinical results. Today, HCC therapy is set to undergo a major revolution, owing to rapid developments in cancer immunotherapy, particularly immune checkpoint inhibitor therapy. Cancer immunotherapy is a novel and promising treatment strategy that differs significantly from conventional therapies in its approach to achieve antitumor effects. In fact, many cancer immunotherapies have been tested worldwide and shown to be effective against various types of cancer;HCC is no exception to this trend. For example, we identified a specific cancer antigen called glypican-3 (GPC3) and performed clinical trials of GPC3-targeted peptide vaccine immunotherapy in patients with HCC. Here, we present an overview of the immune mechanisms for development and progression of HCC, our GPC3-based immunotherapy, and immune checkpoint inhibitor therapy against HCC. Finally, we discuss the future prospects of cancer immunotherapy against HCC. We believe that this review and discussion of cancer immunotherapy against HCC could stimulate more interest in this promising strategy for cancer therapy and help in its further development. 展开更多
关键词 Hepatocellular carcinoma CANCER IMMUNOTHERAPY Immune CHECKPOINT inhibitor GLYPICAN-3 CANCER vaccine Clinical trials CYTOTOXIC T-LYMPHOCYTES
在线阅读 免费下载
The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis
4
作者 Jun-Jie Wang Xin-Yi Gao +1 位作者 Hong-Zhuo Li Shan-Shuang Du 《国际眼科杂志:英文版》 SCIE CAS 2019年第6期1027-1036,共10页
AIM: To evaluate the relative efficacy and safety of besifloxacin for treatment of acute bacterial conjunctivitis.METHODS: A comprehensive search in PubMed, EMBASE Web of Science, Cochrane Central Database and CNKI wa... AIM: To evaluate the relative efficacy and safety of besifloxacin for treatment of acute bacterial conjunctivitis.METHODS: A comprehensive search in PubMed, EMBASE Web of Science, Cochrane Central Database and CNKI was undertaken for randomized controlled trials(RCTs) comparing besifloxacin with other treatments or placebo. The primary outcome measures were clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, and bacterial eradication rates of different kinds of pathogens. Safety outcomes were the number of adverse effects(AEs). The final search was performed on August 2018.RESULTS: Eight RCTs were included. Five studies compared the efficacy and safety of besifloxacin with placebo, 2 studies compared besifloxacin with moxifloxacin, and 1 study compared besifloxacin with gatifloxacin. A total of 3105 patients met the inclusion criteria. Besifloxacin presented higher efficacy and safety than did placebo in clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, bacterial eradication rates of different kinds of pathogens and the number of AEs. There was no significant difference between besifloxacin and moxifloxacin or gatifloxacin in the comparison items mentioned above.CONCLUSION: Besifloxacin is highly effective and safe for treatment of acute bacterial conjunctivitis. Further comparative trials regarding the effect of besifloxacin for treatment of acute bacterial conjunctivitis will aid in treatment decisions. 展开更多
关键词 besifloxacin ACUTE BACTERIAL CONJUNCTIVITIS META-ANALYSIS RANDOMIZED CONTROLLED trials
Compound Kushen injection combined with chemotherapy in the treatment of gastric cancer: a meta-analysis of randomized controlled trials 预览
5
作者 Su-Tong Liu Kai-Qi Su Wen-Xia Zhao 《TMR肿瘤》 2019年第1期118-126,共9页
Objective: This study aims to systematically evaluate the efficacy and safety of compound kushen injection (CKI) in combination with chemotherapy in patients with gastric cancer (GC). Methods: A comprehensive electron... Objective: This study aims to systematically evaluate the efficacy and safety of compound kushen injection (CKI) in combination with chemotherapy in patients with gastric cancer (GC). Methods: A comprehensive electronic search was conducted by searching PubMed, EMBASE, Cochrane Library, Chinese Biological Medical disc, China National Knowledge Infrastructure and Wanfang databases (the last update January 20, 2018). All randomized controlled trials (RCTs) of CKI plus chemotherapy versus chemotherapy alone in GC patients were identified. The quality of each study was evaluated using the Jadad’s scale, and the meta-analysis was performed using Review Manager 5.3 and STATA 14 software. Results: A total of nine studies on 688 cases were included in this study. The results showed that CKI combined with chemotherapy had a better effect on improving patients’ overall response rate (ORR) and life quality. The consequences of Egger’s and Begg’s tests showed there was no significant publication bias. Conclusion: The current evidence showed that CKI may enhance the clinical efficacy of chemotherapy, improve the quality of life and increase the safety in patients with gastric cancer. 展开更多
关键词 Compound kushen INJECTION CHEMOTHERAPY GASTRIC cancer RANDOMIZED controlled trials
在线阅读 下载PDF
Discussions on real-world acupuncture treatments for chronic low-back pain in older adults
6
作者 Arthur Yin Fan Hui Ouyang +7 位作者 Xinru Qian Hui Wei David Dehui Wang Deguang He Haihe Tian Changzhen Gong Amy Matecki Sarah Faggert Alemi 《结合医学学报:英文版》 CAS CSCD 2019年第2期71-76,共6页
Chronic low-back pain(CLBP) is one of the most common pain conditions. Current clinical guidelines for low-back pain recommend acupuncture for CLBP. However, there are very few high-quality acupuncture studies on CLBP... Chronic low-back pain(CLBP) is one of the most common pain conditions. Current clinical guidelines for low-back pain recommend acupuncture for CLBP. However, there are very few high-quality acupuncture studies on CLBP in older adults. Clinical acupuncture experts in the American Traditional Chinese Medicine Association(ATCMA) were interested in the recent grant on CLBP research announced by the National Center for Complementary and Integrative Health. The ATCMA experts held an online discussion on the subject of real-world acupuncture treatments for CLBP in older adults. Seven participants, each with more than 20 years of acupuncture practice, discussed their own unique clinical experience while another participant talked about the potential mechanism of acupuncture in pain management. As a result of the discussion, a picture of a similar treatment strategy emerged across the participants for CLBP in older adults. This discussion shows that acupuncture may have complicated mechanisms in pain management, yet it is effective for the treatment of chronic pain involving maladaptive neuroplasticity;therefore, it should be effective for CLBP in older adults. 展开更多
关键词 Acupuncture PRAGMATIC clinical trials as TOPIC REAL world Treatment strategies Low-back PAIN OLDER ADULTS Discussion
Evaluation on Effectiveness and Safety of Chinese Herbs inTreatment of Sub-health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
7
作者 ZHAO Jun LIAO Xing +3 位作者 ZHAO Hui LI Zhi-geng WANG Nan-yue WANG Li-min 《中国结合医学杂志:英文版》 SCIE CAS CSCD 2019年第6期471-480,共10页
Objective: To evaluate the effectiveness and safety of Chinese herbs in the treatment of sub-health systematical y. Methods: Nine databases were systematicaly and extensively searched to col ect randomized control ed ... Objective: To evaluate the effectiveness and safety of Chinese herbs in the treatment of sub-health systematical y. Methods: Nine databases were systematicaly and extensively searched to col ect randomized control ed trials(RCTs) about Chinese herbs in the treatment of sub-health. The outcomes included overal effective rate, main symptoms, quality of life, etc. Literature screening, data extraction and quality assessment were conducted according to Cochrane Handbook 5.1. Meta-analysis was conducted to the included literature with Review Manager Software.Results: Seventy-two studies involving 9,296 patients with sub-health were included with 4,908 patients in experimental groups and 4,387 patients in control groups. The overal quality of included clinical research was not high. In the aspect of improving overall effective rate, relieving main symptoms, Pittsburgh sleep quality index(PSQI) score, Athens Insomnia Scale(AIS) score, Fatigue Scale-14(FS-14), Cornel Medical Index(CMI) score and discontinuation rate, the effects of experimental groups were better than that of control groups. According to available research reports, adverse reactions in Chinese herb groups were mainly mild gastrointestinal symptoms, which did not affect the treatment.Conclusion: Chinese herbs have a curative effect in the treatment of sub-health. However, there are no clear criteria for diagnosis and curative effectiveness judgment global y, which would affect the accuracy of curative effect evaluation. 展开更多
关键词 SUB-HEALTH RANDOMIZED controlled trials Chinese MEDICINE systematic review
Can we further optimize therapeutic hypothermia for hypoxic-ischemic encephalopathy? 预览
8
作者 Anthony Davies Guido Wassink +2 位作者 Laura Bennet Alistair J. Gunn Joanne O. Davidson 《中国神经再生研究:英文版》 SCIE CAS CSCD 2019年第10期1678-1683,共6页
Perinatal hypoxic-ischemic encephalopathy is a leading cause of neonatal death and disability.Therapeutic hypothermia significantly reduces death and major disability associated with hypoxic-ischemic encephalopathy;ho... Perinatal hypoxic-ischemic encephalopathy is a leading cause of neonatal death and disability.Therapeutic hypothermia significantly reduces death and major disability associated with hypoxic-ischemic encephalopathy;however,many infants still experience lifelong disabilities to movement,sensation and cognition.Clinical guidelines,based on strong clinical and preclinical evidence,recommend therapeutic hypothermia should be started within 6 hours of birth and continued for a period of 72 hours,with a target brain temperature of 33.5 ±0.5℃ for infants with moderate to severe hypoxic-ischemic encephalopathy.The clinical guidelines also recommend that infants be re warmed at a rate of 0.5℃ per hour,but this is not based on strong evidence.There are no randomized controlled trials investigating the optimal rate of rewarming after therapeutic hypothermia for infants with hypoxic-ischemic encephalopathy.Preclinical studies of rewarming are conflicting and results were confounded by treatment with sub-optimal durations of hypothermia.In this review,we evaluate the evidence for the optimal start time,duration and depth of hypothermia,and whether the rate of rewarming after treatment affects brain injury and neurological outcomes. 展开更多
关键词 HYPOXIA-ISCHEMIA hypoxic-ischemic ENCEPHALOPATHY THERAPEUTIC HYPOTHERMIA neuroprotection THERAPEUTIC strategies randomized controlled trials animal models fetal sheep PIGLETS
在线阅读 下载PDF
Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: A concise review 预览
9
作者 Ai-Tong Wang Ying Feng +2 位作者 Hong-Hong Jia Meng Zhao Hao Yu 《世界干细胞杂志:英文版(电子版)》 2019年第4期222-235,共14页
Osteoarthritis (OA) refers to a chronic joint disease characterized by degenerative changes of articular cartilage and secondary bone hyperplasia. Since articular cartilage has a special structure, namely the absence ... Osteoarthritis (OA) refers to a chronic joint disease characterized by degenerative changes of articular cartilage and secondary bone hyperplasia. Since articular cartilage has a special structure, namely the absence of blood vessels as well as the low conversion rate of chondrocytes in the cartilage matrix, the treatment faces numerous clinical challenges. Traditional OA treatment (e.g., arthroscopic debridement, microfracture, autologous or allogeneic cartilage transplantation, chondrocyte transplantation) is primarily symptomatic treatment and pain management, which cannot contribute to regenerating degenerated cartilage or reducing joint inflammation. Also, the generated mixed fibrous cartilage tissue is not the same as natural hyaline cartilage. Mesenchymal stem cells (MSCs) have turned into the most extensively explored new therapeutic drugs in cell-based OA treatment as a result of their ability to differentiate into chondrocytes and their immunomodulatory properties. In this study, the preliminary results of preclinical (OA animal model)/clinical trials regarding the effects of MSCs on cartilage repair of knee joints are briefly summarized, which lay a solid application basis for more and deeper clinical studies on cell-based OA treatment. 展开更多
关键词 OSTEOARTHRITIS MESENCHYMAL STEM cells STEM cell THERAPY CLINICAL trials
在线阅读 免费下载
A meta-analysis of Duhuo Jisheng decoction combined with non-operative therapy on lumbar disc herniation 预览
10
作者 Chen-Yang Zhang Ling Li +2 位作者 Zhao-Yong Li Xiao-Nan Wu Shao-Feng Yang 《TMR临床研究》 2019年第3期115-124,共10页
Objective:To systematically evaluate the cllinical efficacy of Duhuo Jisheng decoction(DHJSD)combined with non-surgical therapy on lumbar disc herniation(LDH).Methods:China Science and Technology Journal Database(VIP)... Objective:To systematically evaluate the cllinical efficacy of Duhuo Jisheng decoction(DHJSD)combined with non-surgical therapy on lumbar disc herniation(LDH).Methods:China Science and Technology Journal Database(VIP),Chinese National Knowledge Infrastructure(CNKI),WanFang Data,PubMed were searched and eligible randomized controlled clinical trials(RCTs)were included.Two reviewers evaluated the quality of the included RCTs and extracted data independently.Then,data analysis was performed with RevMetn 4.2 software.Results:A total of 18 RCTs were enrolled,including 1682 patients.Meta-analysis results showed that the overall response rate of DHJSD combined with non-operative therapy group(treatment group)in the treatment of LDH was better than that of the non-operative therapy group(control group)[OR=4.29,95%CI(3.19,5.76),P<0.001].JOA score of the treatment group was significantly higher than that of control group[OR=3.96,95%CI(3.4,4.52),P<0.001].VAS score was dramatically lower in the treatment group than the control group[OR=-1.58,95%CI(-1.97,-1.18),P<0.001].Conclusion:The clinical efficacy of DHJSD combined with non-surgical therapy is better than that of non-surgical therapy alone.However,due to the low quality of the included literatures,large-scale and high-quality RCTs are still needed for further confirmation. 展开更多
关键词 Duhuo Jisheng decoction (DHJSD) Lumbar disc herniation (LDH) META-ANALYSIS Randomizedcontrolled trials (RCTs)
在线阅读 下载PDF
Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system 预览
11
作者 Florian Simon Nicolaos Floros +2 位作者 Wiebke Ibing Hubert Schelzig Artis Knapsis 《中国神经再生研究:英文版》 SCIE CAS CSCD 2019年第8期1309-1312,共4页
Erythropoietin (EPO) is one of the most successful biopharmaceuticals in history and is used for treating anemia of different origins. However, it became clear that EPO could also work in a neuroprotective, antiapopto... Erythropoietin (EPO) is one of the most successful biopharmaceuticals in history and is used for treating anemia of different origins. However, it became clear that EPO could also work in a neuroprotective, antiapoptotic, antioxidative, angiogenetic and neurotropic way. It causes stimulation of cells to delay cell apoptosis, especially in the central nervous system. In rodent models of focal cerebral ischemia, EPO showed an impressive reduction of infarct size by 30% and improvement of neurobehavioral outcome by nearly 40%. A large animal model dealing with ischemia and reperfusion of the spinal cord showed that EPO could reduce the risk of spinal cord injury significantly. In addition, some clinical studies tested whether EPO works in real live clinical settings. One of the most promising studies showed the innocuousness and improvements in follow-up, outcome scales and in infarct size, of EPO-use in humans suffering from ischemic stroke. Another study ended unfortunately in a negative outcome and an increased overall death rate in the EPO group. The most possible reason was the involvement of patients undergoing simultaneously systemic thrombolysis with recombinant tissue plasminogen activator. An experimental study on rats demonstrated that administration of EPO might exacerbate tissue plasminogen activator-induced brain hemorrhage without reducing the ischemic brain damage. This case shows clearly how useful animal models can be to check negative side effects of a treatment before going into clinical trials. Other groups looked in human trials at the effects of EPO on the outcome after ischemic stroke, relation to circulating endothelial progerdtor cells, aneurysmal subarachnoid hemorrhage, traumatic brain injury, hemoglobin transfusion thresholds and elective first-time coronary artery bypass surgery. Most of the results were pos-让ive, but are based mostly on small group sizes. However, some of the most neglected facts when focusing on experimental setups of ischemia of the central nervous system are issue 展开更多
关键词 ERYTHROPOIETIN apoptosis central nervous system cerebral ISCHEMIA animal model stroke human trials age COMORBIDITY SPINAL cord ISCHEMIA
在线阅读 下载PDF
Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues 预览
12
作者 Yonghong Li Yan Huo +1 位作者 Lei Yu Junzhi Wang 《工程(英文)》 2019年第1期122-131,共10页
Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancer immunotherapy strategy, has been developing very rapidly in recent years. CAR-T cells are genetically modified T cells... Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancer immunotherapy strategy, has been developing very rapidly in recent years. CAR-T cells are genetically modified T cells that can specifically recognize tumor specific antigens on the surface of tumor cells, and then effectively kill tumor cells. At present, exciting results are being achieved in clinical applications of CAR-T cells for patients with hematological malignancies. The research and development of CAR-T cells for various targets and for the treatment of solid tumors have become a hot topic worldwide, so an increasing number of investigational new drug applications (INDAs) and new drug applications (NDAs) of CAR-T cell products are expected to be submitted in future. The quality control and nonclinical research of these products are of great significance in ensuring the safety and effectiveness of these products;however, they also present great challenges and difficulties. This article discusses the general principles of and key issues regarding the quality control and nonclinical research of CAR-T cell products based on their product characteristics and on relevant guidelines for gene and cell therapy products. 展开更多
关键词 CHIMERIC ANTIGEN receptor T cells Quality control NONCLINICAL research Safety EFFICACY Clinical trials Cancer IMMUNOTHERAPY
在线阅读 免费下载
The Substantive Reform of Court Trials: A Transformation of Logic in the Methods of Evidence Investigation-Summary of the Reform Pilot Project in Chengdu 预览
13
作者 Ma Jinghua Wang Jian(Translator) 《当代社会科学(英文)》 2019年第4期59-74,共16页
In the pilot project of the substantive reform of court trials,“unexpected” judgments appeared constantly because the traditional documentary investigation mode has been replaced by an investigation mode under the p... In the pilot project of the substantive reform of court trials,“unexpected” judgments appeared constantly because the traditional documentary investigation mode has been replaced by an investigation mode under the principle of directness and verbalism. This change in the logic of factual judgments has caused a change in the methods of evidence examination. In traditional evidence examination, evidence obtained from investigations is supposed to be genuine and reliable. In the substantive reform of court trials, it is presumed that evidence obtained from investigations cannot be fully trusted and it is easier to ascertain the facts of the case by investigating using the principles of directness, verbalism and individualized judging methods for evidence examinations. In practice, there are three main factors affecting the genuineness of evidence: the cognitive rules of testifiers, the motivation of the subjects who provide evidence, and the methods used by investigators to obtain evidence. Based on any one of these three factors, it cannot be concluded that evidence obtained from investigations is superior to evidence presented in court. The substantive court investigation is more advantageous to establishing the facts of a case than the traditional court investigation. The essential characteristics of the substantive reform of court trials are pursuing reality in essence instead of in form, and using the files of the court trials instead of the files of the investigation to avoid the evidence obtained through investigations from playing a decisive role in the adjudication thus making criminal procedures trial-centered rather than investigation-centered. 展开更多
关键词 the SUBSTANTIVE REFORM of court trials the METHODS of EVIDENCE INVESTIGATION trialcentered REALITY in essence REALITY in form
在线阅读 免费下载
Chinese research into severe ulcerative colitis has increased in quantity and complexity 预览
14
作者 Cheng-Xin Luo Zhong-Hui Wen +5 位作者 Yu Zhen Zhu-Jun Wang Jing-Xi Mu Min Zhu Qin Ouyang Hu Zhang 《世界临床病例杂志》 2018年第3期35-43,共9页
AIM To investigate the current state of research output from Chinese studies into severe ulcerative colitis(SUC)using a bibliometric analysis of publications.METHODS The contents of the Chinese periodical databases WA... AIM To investigate the current state of research output from Chinese studies into severe ulcerative colitis(SUC)using a bibliometric analysis of publications.METHODS The contents of the Chinese periodical databases WANFANG,VIP,and China National Knowledge Infrastructure were searched for all papers regarding UC or SUC published in last the 15 years(from 2001 to 2015).The number of publications in each year was recorded to assess the temporal trends of research output.All SUC related publications were downloaded and the complexity of this research was evaluated with methods described previously.The number of patients with SUC reported each year was recorded and their clinical characteristics were analyzed using information available in the relevant papers.RESULTS There were 13499 publications regarding UC published in Chinese medical journals between 2001 and 2015,of which 201 focused on SUC.The number of publications increased rapidly with more than half of all papers being published in the most recent 5-year period.There was a significant increase in analytical studies and clinical trials over the study period(P<0.01),with research into the management of SUC,included pharmacotherapy,nutrition support as well as surgery,predominating.Almost half(46.2%)of the observational analytical studies and clinical trials focused on Traditional Chinese Medicine,with little research on the efficacy of cyclosporin and infliximab in disease management.About 6222 patients with SUC were reported in the 201 SUC relevant papers,with a ratio of male/female of 1.38.The number of patients reported in each 5-year period significantly increased.The colectomy rate and short-term mortality rate were 7.7%and 0.8%respectively.The most commonly employed operation was total proctocolectomy with ileal pouch-anal anastomosis.CONCLUSION The output and complexity of research related to SUC in China increased significantly over the previous 15 years,however few of these studies focused on salvage therapy. 展开更多
关键词 BIBLIOMETRIC analysis Clinical trials SALVAGE therapy COMPLEXITY SEVERE ULCERATIVE colitis Temporal trends Traditional Chinese Medicine
在线阅读 免费下载
Keeping track of all ongoing colorectal cancer trials using a mobile application:Usability and satisfaction results of the Dutch Colorectal Cancer Group Trials application 预览
15
作者 Joost Huiskens Michael S.Gałek-Aldridge +4 位作者 Jean-Michel Bakker Pim B.Olthof Thomas M.van Gulik Cornelis J.A.Punt Martijn G.H.van Oijen 《临床和转化研究》 2018年第3期35-40,共6页
Background and Aim:Both the number and complexity of medical trials are increasing vastly.To facilitate easy access to concise trial information,a freely available mobile application including all ongoing clinical tri... Background and Aim:Both the number and complexity of medical trials are increasing vastly.To facilitate easy access to concise trial information,a freely available mobile application including all ongoing clinical trials of the Dutch Colorectal Cancer Group(DCCG)was developed.The aim of this study was to investigate the use and user satisfaction over the first 2 years.Methods:The application was launched in January 2015 on iOS and Android platforms.Google Analytics was used to monitor anonymous user data up to February 2017.In addition,an online survey regarding the use and satisfaction among health-care professionals and research affiliates active in the field of colorectal cancer in the Netherlands was conducted.Results:A total of 6173 unique users were identified,of which 1822(30%)were from the Netherlands,representing a total of 16,065 and 10,987(68%)sessions,respectively.The median session duration per day was 01:47 min(IQR 0:51–03:03).The mobile application was mostly used on Monday,Tuesday,and Thursday,and the number of sessions was highest during the following time frames:12–13 pm(9%),17–18 pm(9%),and 13–14 pm(8%).Of 121 survey responses,most were medical doctors(47%),nurses(25%),or researchers(9%),working either in a teaching(40%),academic hospital(32%),or general hospital(19%).83%of all respondents rated the application 4 or higher for satisfaction on a 5-point scale.Highest reported reasons of the use were urgent trial inquiry(57%)and usage during multi-disciplinary meetings(49%).Conclusion:The DCCG Trials application is frequently used,and the majority of users is highly satisfied.Relevance for Patients:Clustering trial information into one platform,such as DCCG trials app,has shown to be useful for medical professionals treating patients with colorectal carcinoma in the Netherlands. 展开更多
关键词 clinical trials colorectal cancer smartphone application
在线阅读 下载PDF
筋骨痛消丸治疗膝骨关节炎疗效的Meta分析
16
作者 王雷 付晓芳 +1 位作者 李无阴 王孝辉 《亚太传统医药》 2018年第2期111-114,共4页
目的:系统评价筋骨痛消丸治疗膝骨关节炎的临床疗效。方法:计算机检索中外数据库中筋骨痛消丸治疗膝骨关节炎的随机对照试验,经过文献筛选、资料提取及质量评价后,采用Review Manager 5.2软件进行Meta分析。结果:最终纳入10篇文... 目的:系统评价筋骨痛消丸治疗膝骨关节炎的临床疗效。方法:计算机检索中外数据库中筋骨痛消丸治疗膝骨关节炎的随机对照试验,经过文献筛选、资料提取及质量评价后,采用Review Manager 5.2软件进行Meta分析。结果:最终纳入10篇文献,共计1399例病例,其中治疗组879例、对照组520例。治疗组予以筋骨痛消丸或中西医结合治疗,对照组予以非甾体抗炎药、硫酸氨基葡萄糖、玻璃酸钠关节腔内注射等西医治疗或阳性中成药治疗。纳入文献的异质性检验(χ^2=8.04,P=0.53〉0.10,I^2=0%〈50%),表明纳入文献同质性好,可采用固定效应模型分析;合并后的效应量OR=3.85,95%CI[2.62,5.67],Z=6.83(P〈0.00001),表明治疗组总有效率高于对照组;本软件绘制的漏斗图显示分布不对称,表明存在发表偏倚的可能性较大。结论:筋骨痛消丸对膝骨关节炎的治疗效果显著,但仍需更多高质量研究进一步论证结论,且需要对其安全性进行评价。 展开更多
关键词 膝骨关节炎 筋骨痛消丸 随机对照试验 META分析
Electrically stimulated cell migration and its contribution to wound healing
17
作者 Guangping Tai Michael Tai Min Zhao 《烧伤与创伤》 2018年第3期183-189,共7页
Naturally occurring electric fields are known to be morphogenetic cues and associated with growth and healing throughout mammalian and amphibian animals and the plant kingdom. Electricity in animals was discovered in ... Naturally occurring electric fields are known to be morphogenetic cues and associated with growth and healing throughout mammalian and amphibian animals and the plant kingdom. Electricity in animals was discovered in the eighteenth century. Electric fields activate multiple cellular signaling pathways such as PI3K/PTEN, the membrane channel of KCNJ15/Kir4.2 and intracellular polyamines. These pathways are involved in the sensing of physiological electric fields, directional cell migration (galvanotaxis, also known as electrotaxis), and possibly other cellular responses. Importantly, electric fields provide a dominant and over-riding signal that directs cell migration. Electrical stimulation could be a promising therapeutic method in promoting wound healing and activating regeneration of chronic and non-healing wounds. This review provides an update of the physiological role of electric fields, its cellular and molecular mechanisms, its potential therapeutic value, and questions that still await answers. 展开更多
关键词 WOUND HEALING Ion transport ENDOGENOUS electric fields Electrical STIMULATION Cell migration Clinical trials
Upgraded role of autophagy in colorectal carcinomas 预览
18
作者 Evangelos Koustas Panagiotis Sarantis +1 位作者 Athanassios G Papavassiliou Michalis V Karamouzis 《世界胃肠肿瘤学杂志:英文版(电子版)》 CAS 2018年第11期367-369,共3页
Autophagy is a basic catabolic process closely associated with degradation of cellular components.The role of autophagy in colorectal cancer(CRC)remains controversial.The mechanism of autophagy has been identified as ... Autophagy is a basic catabolic process closely associated with degradation of cellular components.The role of autophagy in colorectal cancer(CRC)remains controversial.The mechanism of autophagy has been identified as protecting mechanism against tumorigenesis by isolation of damaged organelles or as cytoprotective provides energy in hypoxic regions of CRC tumors.Mutations in proto-oncogenes,such as RAS and BRAF,have been associated with autophagy initiation through signaling pathways of BRAF/MEK/ERK and PI3K/AKT/mTOR.A combination therapy of chemotherapeutic agents and autophagy inhibitors such as hydroxychloroquine or immunotherapy might represent a major step that could be evaluated as a putative novel therapeutic strategy in CRC patients. 展开更多
关键词 AUTOPHAGY TUMORIGENESIS CLINICAL trials AUTOPHAGY INHIBITORS COLORECTAL CANCER
在线阅读 免费下载
Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes 预览
19
作者 Manfred Paul Stapff 《世界糖尿病杂志:英文版(电子版)》 2018年第12期252-257,共6页
AIM To evaluate the effect on cardiovascular outcomes of sodium-glucose co-transporter-2(SGLT2)inhibitors in a real world setting by analyzing electronic medical records.METHODS We used TriNetX,a global federated rese... AIM To evaluate the effect on cardiovascular outcomes of sodium-glucose co-transporter-2(SGLT2)inhibitors in a real world setting by analyzing electronic medical records.METHODS We used TriNetX,a global federated research network providing statistics on electronic health records(EHR).The analytics subset contained EHR from approximately 38 Million patients in 35 Health Care Organizations in the United States.The records of 46,909 patients who had taken SGLT2 inhibitors were compared to 189,120 patients with dipeptidyl peptidase(DPP)4 inhibitors.We identified five potential confounding factors and built respective strata:elderly,hypertension,chronic kidney disease(CKD),and co-medication with either insulin or metformin.Cardiovascular events were counted as stroke(ICD10 code:I63)or myocardial infarction(ICD10:I21)occurring within three years after the first instance of the respective medication in the patients’records.RESULTS Of the 46909 patients with SGLT2 inhibitors in their EHR,1667 patients(3.6%)had an ICD code for stroke or for myocardial infarction within the first three years after the first instance of the medication.In the control group,there were 10680 events of 189120 patients(5.6%),which represents a risk ratio of 0.63(95%CI:0.60-0.66).The overall incidence of stroke or myocardial infarction in the strata with a potential confounding risk factor reached from 4.9%in patients taking metformin to 12.5%in the stratum with the highest risk(concomitant CKD).In all strata,the difference in risk of experiencing a cardiovascular event was similarly in favor of SGLT2 vs control,with Risk Ratio ranging from 0.62 to 0.81.CONCLUSION Real world data replicated the results from randomized clinical trials,confirmed the cardiovascular advantages of SGLT2 inhibitors,and showed its applicability to the US population. 展开更多
关键词 Sodium-glucose co-transporter-2 INHIBITORS CARDIOVASCULAR events Clinical trials Electronic medical RECORDS Dipeptidyl PEPTIDASE 4 INHIBITORS Real world evidence Diabetes
在线阅读 免费下载
Aloe Royal Jelly Powder Contributes to Maintain Normal Immunity: a Randomized Clinical Trial 预览
20
作者 Yi Yang Chen Zhang +7 位作者 Xiaoguang Zhu Mei Huang Xuemei Wang Yanan Wang Xiaotong Liu Qian Liu Fengjuan Zhang Weiwei Li 《医学科学进展杂志(英文)》 2018年第4期125-128,共4页
Objective: To study the safety and the function of maintaining normal immunity of product with royal jelly lyophilized powder and whole-leaf aloe drying powder as main raw materials. Methods: Selected 125 subjects qua... Objective: To study the safety and the function of maintaining normal immunity of product with royal jelly lyophilized powder and whole-leaf aloe drying powder as main raw materials. Methods: Selected 125 subjects qualified for inclusion/exclusion criteria for a trial test.(The trial group lost 9 subjects. The control group lost 6 subjects.54 effective subjects of trial group includes 12 men and 42 women. 56 effective subjects of control group including 9 men and 47 women.) The trial group was evaluated by self-control and inter-group comparison, after 90 days of continuous use of aloe royal jelly. Results: There are significant differences in the overall feeling, physiological feeling, psychological feeling and comprehensive evaluation of the individuals in the trial group after 90 days (P<0.001), which are higher than before. The control group has no statistically significant difference in the comprehensive evaluation before and after the trial (P>0.05). The ratio of CD4/CD8, IgG, IgA and IgM in the trial group and the placebo control group are above the normal low-limit. There is no obvious abnormality in indicators of blood test, blood biochemistry, liver and kidney function and other clinical tests. Conclusion: Aloe royal jelly powder contributes to maintain normal immune function and has no harmful effect to the health of subjects. 展开更多
关键词 ROYAL JELLY ALOE MAINTAIN NORMAL IMMUNITY Human feeding trials
在线阅读 免费下载
上一页 1 2 250 下一页 到第
使用帮助 返回顶部 意见反馈